Mankind Pharma IPO subscribed 15.32 times

This will be one of the largest public issues by a domestic drug manufacturer after the ₹6,480-crore IPO of Gland Pharma in 2020. The qualified institutional buyers (QIB) category was subscribed 49 times, while the non-institutional investors or high net-worth individuals’ portion was subscribed 3.8 times. However, the retail investor’s portion was under-subscribed at 92%.

Generated by Feedzy